Àº¿À°å³Ø¤Î³¤Ï·¤Ç¤ó¤¹

¤¢¤¿¤ê¤Þ¤¨¤Ë²Ê³ØÅª¤Ê°åÎŤò¤·¤¿¤¤¤±¤É¡ÊÃæ¿È¤Î¤Ê¤¤½ñ¸Ë¤¬Áý¤¨¤Þ¤·¤¿¡Ë

F2¡ÊÅý¹ç¼ºÄ´¾É¤Ê¤É¡Ë

[ ¥ê¥¹¥È | ¾ÜºÙ ]

µ­»ö¸¡º÷
¸¡º÷

Á´1¥Ú¡¼¥¸

[1]

ɽÂê¡§ÂèÆóÀ¤Âå¹³Àº¿ÀÉÂÌô¤Ø¤ÎÊѹ¹¤Ë¤è¤ë¿´·ì´É·Ï¥ê¥¹¥¯¾å¾º
ÌÜŪ¡§Åý¹ç¼ºÄ´¾É¤¢¤ë¤¤¤ÏÅý¹ç¼ºÄ´´¶¾ð¾ã³²¤Ë¤ª¤¤¤Æ¡¢Ä¹´üÅêÍ¿¤Ë¤è¤ë¿´·ì´É·Ï¤Ø¤ÎÍ­³²È¿±þ¤òÌÀ¤é¤«¤Ë¤¹¤ë¡£
ÊýË¡¡§1985ǯ¤«¤é2004ǯ¤Þ¤Ç¤ÎÈóÄê·¿¹³Àº¿ÀÉÂÌô¤Ë¤Ä¤¤¤Æ¡¢PubMed¤Ë¤è¤ê¡¢atypical antipsychotics, obesity, weight, diabetes mellitus, dyslipidemia, hypercholesterolemia, lipids, second generation antipsychotics, antipsychotic agents, schizophrenia, metabolic syndrome, cardiovascular disease, and cardiovascular risk factors¤ò¥­¡¼¥ï¡¼¥É¤È¤·¤Æ¸¡º÷¡£ÆÀ¤é¤ì¤¿Ê¸¸¥¤òÉ®¼Ô¤é¤¬Àººº¡£
·ë²Ì¡Ê¥Ç¡¼¥¿¤ÎÅý¹ç¡Ë¡§ÌôºÞ¤ÎÁªÂò¤Ï´µ¼Ô¤Ø¤Î¼£ÎŸú²Ì¤ò´ð½à¤ËÁªÂò¤µ¤ì¤ë¤Ù¤­¤Ç¤¢¤ë¡£¤¿¤À¡¢£²¤Ä¤ÎÌôºÞ¤Î¼£ÎŸú²Ì¤¬Æ±¤¸¤Ê¤é¡¢Â¾¤ÎÎ×¾²¾å¤Î°ÕµÁ¤Ë¤è¤êÌôºÞ¤ÎÁªÂò¤¬¤Ê¤µ¤ì¤Æ¤â¤è¤¤¡£¥ª¥é¥ó¥¶¥Ô¥ó¤ä¥¯¥í¥¶¥Ô¥ó¤«¤é¥ê¥¹¥Ú¥ê¥É¥ó¤ËÊѹ¹¤Ç¿´·ì´É·Ï¤Î¥ê¥¹¥¯¤¬33¡ó¸º¾¯¡ÊµÕ¤Ê¤éƱΨÁý²Ã¡Ë¤¹¤ë¡£
¤Þ¤È¤á¡§ÂèÆóÀ¤Âå¤ÎÌôºÞ¤ÎÁªÂò¤Ë¤è¤ê¿´·ì´É·Ï¤Î¥ê¥¹¥¯¤Ï°Û¤Ê¤ë¤¬¡¢ÌôºÞ¤òÊѹ¹¤·¤¿¾ì¹ç¤Î±Æ¶Á¤Ë¤Ä¤¤¤Æ¸ÀµÚ¤Ç¤­¤ë¤Û¤É¥Ç¡¼¥¿¤ÏÃßÀѤµ¤ì¤Æ¤¤¤Ê¤¤¡£Á°¸þ¤­¸¦µæ¤¬É¬Íס£
Êó¹ðÃÏ¡§University of Florida, Gainesville
½Ðŵ¡§Ried LD, Renner BT, McConkey JR, Bengtson MA, Lopez LM. , Increased cardiovascular risk with second-generation antipsychotic agent switches. J Am Pharm Assoc (Wash DC). 2006 Jul-Aug;46(4):491-8; quiz 499-501.
PMID¡§16913393

¾¶Ï¿¤Î¤ß¡£
¥ª¥é¥ó¥¶¥Ô¥ó¤Ï¡¢¤È¤Æ¤â¤¤¤¤Ìô¤Ç¡¢ÉþÍѤ·¤ÆÍî¤ÁÃ夤¤¿¡¢¤È¤¤¤¦´µ¼Ô¤µ¤ó¤â¿¤¤¡£¤¿¤À¡¢ÅüǢɤòͶȯ¤¹¤ë¾ì¹ç¤¬¤¢¤ë¤È¤¤¤¦°ìÅÀ¤Ç¡¢»È¤¤¤Å¤é¤¤¤È¤³¤í¤¬¤¢¤ë¡£
¤³¤Î¤¿¤á¡¢¿ÇÎŤò¤·¤Æ¤¤¤Æ¡¢¤â¤·ÅüǢɤòͶȯ¤·¤¿¤é¡¢¤È¤¤¤¦É԰¤˶î¤é¤ì¤ë¤³¤È¤¬¤¢¤ë¡£
·ìÅü¤¬¹â¤¤¤È¡¢»È¤¤¤¿¤¯¤Ê¤¯¤Ê¤ë¡£
¤¿¤À¡¢´µ¼Ô¤µ¤ó¤Ë¤è¤Ã¤Æ¤Ï¡¢Â¾ºÞ¤ËÊѹ¹¤¹¤ë¤È¡¢¤È¤¿¤ó¤ËÉÔÄ´¤È¤Ê¤ëÊý¤â¡£
¤½¤¦¤¤¤¦¤È¤­¡¢º¤¤ë¡£
É԰¤½¤¦¤Ê´µ¼Ô¤µ¤ó¤ÎÁ°¤Ç¤Ï¡ÖÂç¾æÉספȸÀ¤¤Â³¤±¤ë¤·¤«¡¢¤Ê¤¤¤±¤ì¤É¡£

ÅüǢɤÎÏäΥ¢¥Õ¥£¥ê¥¨¡¼¥È¤Ë¤ª²Û»Ò²°¤µ¤ó¤Ê¤ó¤Æ¤É¤¦¤Ç¤·¤ç¤¦¡£
¸ý¤ÈÀ­³Ê¤¬°­¤¤¤Î¤Ç¡¢¤¹¤ß¤Þ¤»¤ó¡£

ɽÂê¡§21ǯ´Ö¤Î·Ð²á´Ñ»¡¤Ë¤è¤ê¡¢Àº¿À²Ê¼õ¿Ç¤·¤¿¾®»ù´µ¼Ô¤Î¾®»ù´ü¤ÎIQ¤Ï¡¢¤Î¤Á¤ËÅý¹ç¼ºÄ´¾É¤È¤Ê¤Ã¤¿¾ì¹ç¤Î·ë²Ì¤òͽ¸«¤¹¤ë¡ÊActa Psychiatr Scand. 2002 Aug;106(2):139-42¡Ë
ÌÜŪ¡§Åý¹ç¼ºÄ´¾É¤òȯ¾É¤¹¤ëÁ°¤ËÀº¿À²Ê¼õ¿Ç¤·¤¿»ùƸ¤Ï¡¢¤Î¤Á¤ËÀº¿Àɤ˿®¶Ä¤·¤Æ¤·¤Þ¤Ã¤¿¾ì¹ç¡¢ÆÃ¤Ë°­°Õ¤Î¤¢¤ëɤËÃͤ¹¤ë¤È¤â¤¤¤¨¤ë¡£¤½¤ì¤é¤Î»ùƸ¤Î21ǯ¸å¤Î·ë²Ì¤Ë¤Ä¤¤¤ÆÄ´ºº¤ò¹Ô¤Ã¤¿¡£
ÊýË¡¡§Àº¿À²Ê¼õ¿Ç¤·¡¢¤Î¤Á¤ËÅý¹ç¼ºÄ´¾É¤È¿ÇÃǤµ¤ì¤¿»ùƸ51Îã¤ò¡¢Ê¿¶Ñ21ǯ¡¢·Ð²á´Ñ»¡»ë¤·¤¿¡£¾®»ù´ü¤Î¿Í¸ýưÂÖŪ¡¢Î×¾²Åª¡¢¤Þ¤¿ÁÛÄꤵ¤ì¤ëɰøÏÀ¤Ë¤è¤ëÆÃħ¤ò¡¢¿ÇÎÅÏ¿¤«¤é¸¡Æ¤¤·¤¿¡£Î×¾²¾å¤Îħ¸õ¡¢¼Ò²ñµ¡Ç½¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶·¤ò·Ð²á´Ñ»¡¤·¤¿¡£Í½Â¬¤Ë±Æ¶Á¤·¤½¤¦¤Ê°ø»Ò¤ò¸¡Æ¤¤·¤¿¡£
·ë²Ì¡§·ë²Ì¤ÏÉÔÎɤǤ¢¤ê¡¢7Îã¡Ê14¡ó¡Ë¤Ï»àË´¤·¤Æ¤¤¤¿¡£¾®»ù´ü¤ÎIQ¤Ï¼Ò²ñŬ±þ¾õ¶·(F=5.1, P=0.01)¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶· (F=5.2, P=0.01)¤ò¶¯ÎϤËͽ¬¤·¤Æ¤¤¤¿¤¬¡¢Î×¾²Ä§¸õ¤È¤Ï´Ø·¸¤¬¤Ê¤«¤Ã¤¿¡£Â¾¤Î°ø»Ò¤Ï̵´Ø·¸¤Ç¤¢¤Ã¤¿¡£
¤Þ¤È¤á¡§¾®»ù´ü¤ÎÄ㤤IQ¤Ï¡¢¤Ò¤È¤¿¤ÓÅý¹ç¼ºÄ´¾É¤¬È¯¾É¤·¤¿¾ì¹ç¡¢¼Ò²ñŬ±þ¾õ¶·¤È¥µ¡¼¥Ó¥¹ÍøÍѾõ¶·¤Ë¤Ä¤¤¤Æ¡¢¹¥¤Þ¤·¤¯¤Ê¤¤±Æ¶Á¤¬¤¢¤ë¡£
Êó¹ðÃÏ¡§London¡¤UK
½Ðŵ¡§Munro JC, Russell AJ, Murray RM, Kerwin RW, Jones PB. IQ in childhood psychiatric attendees predicts outcome of later schizophrenia at 21 year follow-up. Acta Psychiatr Scand. 2002 Aug;106(2):139-42.
PMID¡§12121212


¡¡´¶ÁÛ
¡¡ºòÆü¡¢ID12121211¤Îµ­»ö¤òÆÉ¤ó¤À¤Î¤Ç¡¢¥­¥êÈÖ¤òÆÉ¤ó¤Ç¤ß¤¿¡£·ÇºÜ¤Ï¸åÆü¤Ë¤·¤è¤¦¤«¤È»×¤Ã¤¿¤¬¡¢Åöľ¤Ê¤Î¤Ç¡¢¤³¤Ã¤Á¤Ë¤·¤¿¡£
¡¡Åý¹ç¼ºÄ´¾É¤ÈÀº¿ÀÃÙÂڤιçÊ»Îã¤Ç¡¢Åý¹ç¼ºÄ´¾Éȯ¾É¸å¤Ë¡¢¼Ò²ñŬ±þ¾õ¶·¤Ë¤«¤Ê¤ê°­±Æ¶Á¤¬¤¢¤ë¤È¤¤¤¦¤Î¤Ï¡¢¤½¤ÎÄ̤ê¤À¤È»×¤¦¡£
¡¡Àº¿ÀÃÙÂÚ¤Îͽ¸å¤Ë¤Ä¤¤¤Æ¡¢»º¶È³×Ì¿Á°¡¢ÆüËܤλº¶È³×Ì¿Á°¤Ç¤â¤¤¤¤¤Î¤À¤¬¡¢¤¿¤È¤¨¤Ð¹¾¸Í»þÂå¤Ë¤ÏÇÀ¶È¤È¤¤¤¦°ìÄê¤Î¿¦¤¬¤¢¤Ã¤Æ¡¢¤½¤ì¤ò¤ä¤Ã¤Æ¤¤¤ì¤Ð¤è¤«¤Ã¤¿¡¢Â¼Íî¤Ç狼¤¬½õ¤±¤Æ¤¯¤ì¤Æ¤¤¤¿¤Î¤Ç¡¢º£¤Û¤É¡¢»Ù±ç¤«¤éÈ´¤±Íî¤Á¤Æ¤·¤Þ¤¦¤³¤È¤Ï¤Ê¤«¤Ã¤¿¡¢¤È¤¤¤¦ÀâÌÀ¤¬¤Ê¤µ¤ì¤ë¤³¤È¤¬¤¢¤ë¡£
¡¡¤½¤¦¤¤¤¦¤Î¤Ê¤é¡¢¤½¤¦¤Ê¤Î¤À¤í¤¦¡£
¡¡¤Ç¤â¡¢¿©ÎÈÀ¸»º¤¬¸Â¤é¤ì¤ë¤È¤¤¤¦¸½¼Â¤ÎÀ©Ì󤬤¢¤ë¤¿¤á¤Ë¡¢¤è¤ê¼ÂÎϼçµÁ¤È¤Ê¤é¤¶¤ë¤ò¤¨¤Ê¤¤¡¢Æ¯¤«¤¶¤ë¼Ô¿©¤¦¤Ù¤«¤é¤º¡¢¤È¤¤¤¦»þÂå¡¢ËÜÅö¤Ë¤½¤¦¤À¤Ã¤¿¤Î¤À¤í¤¦¤«¡£
¡¡¤½¤ó¤Ê¿Í¤â¤¤¤ë¤À¤í¤¦¤±¤É¡¢»Ä¤ê¤Ï¡Ö¤¢¤Ã¤µ¤ê¡¢»à¤ó¤Ç¤¿¤ó¤¸¤ã¤Ê¤¤¤Î¡©¡×¤È¤â¹Í¤¨¤Æ¤·¤Þ¤¦¡£


Á´1¥Ú¡¼¥¸

[1]


.
evi*enc*_*f_p*ychia*ry
evi*enc*_*f_p*ychia*ry
ÃËÀ­ / Èó¸ø³«
¿Íµ¤ÅÙ
Yahoo!¥Ö¥í¥°¥Ø¥ë¥× - ¥Ö¥í¥°¿Íµ¤Å٤ˤĤ¤¤Æ

²áµî¤Îµ­»ö°ìÍ÷

¸¡º÷ ¸¡º÷
Æü ·î ²Ð ¿å ÌÚ ¶â ÅÚ
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

¤è¤·¤â¤È¥Ö¥í¥°¥é¥ó¥­¥ó¥°

¤â¤Ã¤È¸«¤ë

¤ß¤ó¤Ê¤Î¹¹¿·µ­»ö